Porownywarka

Dulaglutide vs CagriSema side-by-side

Zestaw do czterech peptydów według statusu dowodów, mechanizmów, dawkowania z badań, skutków ubocznych i referencji.

Wybrane (2/4)

DulaglutideCagriSema

Udostępnij porównanie peptydów

Wlasciwosc	Dulaglutide	CagriSema
Kategoria	Redukcja masy	Redukcja masy
Znany tez jako	Trulicity	Semaglutide + Cagrilintide
Zatwierdzony przez FDA	Tak	Nie
Status kliniczny	FDA Approved - Type 2 diabetes Pre Przedkliniczne I Faza I II Faza II III Faza III IV Faza IV FDA Zatwierdzone przez FDA	NDA submitted Dec 18, 2025; FDA decision expected Q4 2026. Pre Przedkliniczne I Faza I II Faza II III Faza III IV Faza IV FDA Zatwierdzone przez FDA
Czego oczekiwac	Blood sugar control, weight management, diabetes	Maximum weight loss, combination therapy, obesity
Jak dziala	Dulaglutide is presented as a GLP-1 receptor agonist. The supplied mechanism states that GLP-1 receptor activation supports insulin release when glucose is present, reduces glucagon, and slows gastric emptying. The molecule is described as a modified GLP-1 peptide attached to a human antibody Fc fragment; the source says this larger Fc-linked design reduces rapid renal clearance and helps protect the peptide from DPP-4 degradation. Appetite and modest weight-related effects are attributed in the source to GLP-1 signaling in hunger-regulating brain regions.	CagriSema combines semaglutide, a GLP-1 receptor agonist, with cagrilintide, a long-acting amylin analog. The source links semaglutide to insulin response after meals, delayed gastric emptying and fullness signaling, while cagrilintide is described as acting through amylin-related satiety pathways in the brain. The proposed research rationale is that concurrent GLP-1 and amylin signaling may produce stronger appetite effects than either pathway alone.
Typowe dawkowanie	1.5-4.5 mg weekly · Once weekly	Limited community data available · See research protocols
Dawkowanie z badań	0.75mg weekly (starting) · Long-term / chronic use · Subcutaneous injection weekly	Semaglutide 2.4 mg + cagrilintide 2.4 mg weekly · Weekly · Long-term use expected · Subcutaneous injection weekly
Typowy czas trwania	Long-term / chronic use	Long-term use expected
Podanie	Subcutaneous injection weekly	Subcutaneous injection weekly
Timing	Before bed or morning (fasted) Take on empty stomach	-
Poziom dowodów	Zatwierdzone przez FDA	Badania kliniczne
Mozliwe skutki uboczne	Nausea (Listed by source; gastrointestinal effects are described as typical downsides.) Diarrhea (Listed by source; gastrointestinal effects are described as typical downsides.) Vomiting (Listed by source.) +7 więcej Abdominal pain (Listed by source.) Injection site reactions (Listed by source.) Hypoglycemia (with insulin/sulfonylureas) (Source qualifies this risk as occurring with insulin or sulfonylureas.) Pancreatitis (Listed by source.) Gallbladder problems (Listed by source.) BOXED WARNING: Thyroid C-cell tumors (Source states this boxed warning is based on rodent data.) FDA approved (Trulicity) (Listed in the source side-effects array, but this is a regulatory/identity note rather than an adverse effect.)	Nausea (Reported as a gastrointestinal adverse effect in the source.) Vomiting (Reported as a gastrointestinal adverse effect in the source.) Diarrhea (Reported as a gastrointestinal adverse effect in the source.) +4 więcej Constipation (Reported as a gastrointestinal adverse effect in the source.) Gastrointestinal events (The source reports 72-80% with CagriSema compared with 34-40% for placebo.) Higher gastrointestinal effects than semaglutide alone (Listed in the source side-effect field.) Investigational status (The source notes that CagriSema is not yet approved.)
Podsumowanie researchu	The source characterizes Dulaglutide as supported by human clinical evidence rather than only animal work. It cites the AWARD program for glucose-lowering evidence across multiple type 2 diabetes contexts. It also highlights the 2019 Lancet REWIND trial, which followed more than 9,900 participants for a median period exceeding five years; about 69% reportedly had no previous cardiovascular disease. In that trial summary, major cardiovascular events were lower with dulaglutide than placebo, reported as 12.0% versus 13.4% with a hazard ratio of 0.88. The source notes gastrointestinal tolerability issues such as nausea and diarrhea and states that the class carries a boxed warning about thyroid C-cell tumors based on rodent findings.	The supplied research summary describes two phase 3 REDEFINE studies. In REDEFINE 1, about 3,400 adults with overweight or obesity without diabetes were followed for 68 weeks; reported average body-weight change was about 20.4% with CagriSema, compared with 14.9% for semaglutide, 11.5% for cagrilintide and 3.0% for placebo. REDEFINE 2 enrolled adults with type 2 diabetes and is described as meeting endpoints for weight reduction and HbA1c improvement versus placebo. The source also notes that the approximately 20% result was below Novo Nordisk's 25% target, and that gastrointestinal events were the most common adverse effects.
Referencje	Źródło Źródło +1 więcej Źródło	New England Journal of Medicine New England Journal of Medicine +2 więcej American Diabetes Association Novo Nordisk
Pełny profil	Zobacz szczegóły	Zobacz szczegóły

Zapisz to porównanie

Trzymaj ten zestaw researchowy pod reka na darmowym koncie PeptiGuide.

Zapisz porównanie - darmowe konto

Trackuj swoja ścieżkę peptydówa

Zamien research w prywatny log protokołu, gdy będziesz gotowy.

Trackuj ścieżkę peptydówa

Wyłącznie edukacyjnie. Te informacje są agregowane z publicznych badań i raportów społeczności. To nie jest poradą medyczną, a informacje o dawkowaniu są opisowe, nie rekomendacyjne. Zawsze konsultuj się z wykwalifikowanym specjalistą ochrony zdrowia.

Wlasciwosc

Dulaglutide

CagriSema

Kategoria

Redukcja masy

Znany tez jako

Trulicity

Semaglutide + Cagrilintide

Zatwierdzony przez FDA

Tak

Nie

Status kliniczny

FDA Approved - Type 2 diabetes

Pre
Przedkliniczne
I
Faza I
II
Faza II
III
Faza III
IV
Faza IV
FDA
Zatwierdzone przez FDA

NDA submitted Dec 18, 2025; FDA decision expected Q4 2026.

Pre
Przedkliniczne
I
Faza I
II
Faza II
III
Faza III
IV
Faza IV
FDA
Zatwierdzone przez FDA

Czego oczekiwac

Blood sugar control, weight management, diabetes

Maximum weight loss, combination therapy, obesity

Jak dziala

Dulaglutide is presented as a GLP-1 receptor agonist. The supplied mechanism states that GLP-1 receptor activation supports insulin release when glucose is present, reduces glucagon, and slows gastric emptying. The molecule is described as a modified GLP-1 peptide attached to a human antibody Fc fragment; the source says this larger Fc-linked design reduces rapid renal clearance and helps protect the peptide from DPP-4 degradation. Appetite and modest weight-related effects are attributed in the source to GLP-1 signaling in hunger-regulating brain regions.

CagriSema combines semaglutide, a GLP-1 receptor agonist, with cagrilintide, a long-acting amylin analog. The source links semaglutide to insulin response after meals, delayed gastric emptying and fullness signaling, while cagrilintide is described as acting through amylin-related satiety pathways in the brain. The proposed research rationale is that concurrent GLP-1 and amylin signaling may produce stronger appetite effects than either pathway alone.

Typowe dawkowanie

1.5-4.5 mg weekly · Once weekly

Limited community data available · See research protocols

Dawkowanie z badań

0.75mg weekly (starting) · Long-term / chronic use · Subcutaneous injection weekly

Semaglutide 2.4 mg + cagrilintide 2.4 mg weekly · Weekly · Long-term use expected · Subcutaneous injection weekly

Typowy czas trwania

Long-term / chronic use

Long-term use expected

Podanie

Subcutaneous injection weekly

Timing

Before bed or morning (fasted)

Take on empty stomach

Poziom dowodów

Zatwierdzone przez FDA

Badania kliniczne

Mozliwe skutki uboczne

Nausea (Listed by source; gastrointestinal effects are described as typical downsides.)
Diarrhea (Listed by source; gastrointestinal effects are described as typical downsides.)
Vomiting (Listed by source.)

+7 więcej

Abdominal pain (Listed by source.)
Injection site reactions (Listed by source.)
Hypoglycemia (with insulin/sulfonylureas) (Source qualifies this risk as occurring with insulin or sulfonylureas.)
Pancreatitis (Listed by source.)
Gallbladder problems (Listed by source.)
BOXED WARNING: Thyroid C-cell tumors (Source states this boxed warning is based on rodent data.)
FDA approved (Trulicity) (Listed in the source side-effects array, but this is a regulatory/identity note rather than an adverse effect.)

Nausea (Reported as a gastrointestinal adverse effect in the source.)
Vomiting (Reported as a gastrointestinal adverse effect in the source.)
Diarrhea (Reported as a gastrointestinal adverse effect in the source.)

+4 więcej

Constipation (Reported as a gastrointestinal adverse effect in the source.)
Gastrointestinal events (The source reports 72-80% with CagriSema compared with 34-40% for placebo.)
Higher gastrointestinal effects than semaglutide alone (Listed in the source side-effect field.)
Investigational status (The source notes that CagriSema is not yet approved.)

Podsumowanie researchu

The source characterizes Dulaglutide as supported by human clinical evidence rather than only animal work. It cites the AWARD program for glucose-lowering evidence across multiple type 2 diabetes contexts. It also highlights the 2019 Lancet REWIND trial, which followed more than 9,900 participants for a median period exceeding five years; about 69% reportedly had no previous cardiovascular disease. In that trial summary, major cardiovascular events were lower with dulaglutide than placebo, reported as 12.0% versus 13.4% with a hazard ratio of 0.88. The source notes gastrointestinal tolerability issues such as nausea and diarrhea and states that the class carries a boxed warning about thyroid C-cell tumors based on rodent findings.

The supplied research summary describes two phase 3 REDEFINE studies. In REDEFINE 1, about 3,400 adults with overweight or obesity without diabetes were followed for 68 weeks; reported average body-weight change was about 20.4% with CagriSema, compared with 14.9% for semaglutide, 11.5% for cagrilintide and 3.0% for placebo. REDEFINE 2 enrolled adults with type 2 diabetes and is described as meeting endpoints for weight reduction and HbA1c improvement versus placebo. The source also notes that the approximately 20% result was below Novo Nordisk's 25% target, and that gastrointestinal events were the most common adverse effects.

Referencje

Źródło Źródło

+1 więcej

Źródło

New England Journal of Medicine New England Journal of Medicine

+2 więcej

American Diabetes Association Novo Nordisk

Pełny profil

Zobacz szczegóły